Organoids and Spheroids Market Report 2024

The organoids and spheroids market size has grown exponentially in recent years. It will grow from $0.93 billion in 2023 to $1.16 billion in 2024 at a compound annual growth rate (CAGR) of 24.4%. The growth during the historic period can be attributed to several factors, rapid advancements in stem cell research and 3D cell culture technologies, increased funding and investments, a rise in chronic diseases, growing use of organoids and spheroids for drug screening and toxicology studies, progress in regenerative and personalized medicine, and supportive regulatory frameworks for advanced cell culture models in research.

The organoids and spheroids market size is expected to see exponential growth in the next few years. It will grow to $2.78 billion in 2028 at a compound annual growth rate (CAGR) of 24.5%. The projected growth during the forecast period can be attributed to several factors, ongoing technological advancements, the expansion of personalized medicine, improved applications in cancer research, evolving ethical and regulatory standards, a rise in commercial products and services related to organoid and spheroid technologies, and increased educational efforts to train researchers in these technologies. Major trends expected during this period include the integration of advanced technologies, the expansion of high-throughput screening methods using organoids for drug discovery, advancements in 3D bioprinting and biofabrication, increased use of organoids for cancer modeling, and the integration of organoids with microfluidic systems.

The growing demand for cell therapy and tissue engineering is expected to drive the expansion of the organoids and spheroids market. Cell therapy and tissue engineering involve using living cells or engineered tissues to replace, repair, or regenerate damaged tissues and organs. The rising interest in these fields is due to their potential to treat previously incurable conditions and offer innovative solutions in regenerative medicine. Organoids and spheroids are crucial in these applications, used for modeling complex tissues and testing therapeutic methods in vitro. For example, in June 2021, the Cancer Research Institute, a US-based cancer research organization, reported that 2,073 cellular therapy agents were added to the pipeline in 2021, a 38% increase from the previous year. Additionally, there were 688 clinical trials for CAR-T therapies and around 398 for other cell therapies in 2021. This growing demand for cell therapy and tissue engineering is expected to boost the organoids and spheroids market.

Leading companies in the organoids and spheroids market are advancing solutions such as 3D primary human hepatocyte (PHH) liver spheroids to improve drug discovery and disease modeling. These 3D liver spheroids are clusters of liver cells cultured in three dimensions to more accurately replicate liver function for research and drug testing. For instance, in June 2021, Corning Inc., a US-based technology firm, introduced HepGo Assay-Ready 3D Liver Spheroid Kits. These kits provide pre-formed, assay-ready 3D liver spheroids, simplifying the process for customers and allowing for more efficient and standardized in vitro assays.

In May 2021, Crown Bioscience International, a US-based life science company, acquired OcellO B.V., a Netherlands-based firm specializing in organoid-based drug discovery for oncology and immunology. The acquisition, for an undisclosed amount, will enhance CrownBio’s in vitro services by integrating OcellO’s expertise in high-content imaging with CrownBio’s existing screening and immunotherapy assessment capabilities.

Major companies operating in the organoids and spheroids market are Thermo Fisher Scientific Inc., Merck KGaA, Corning Incorporated, Lonza Group AG, StemCell Technologies Canada Inc., Greiner Bio-One International AG, Promega Corporation, Molecular Devices LLC, American Type Culture Collection (ATCC), Mimetas B.V., InSphero AG, HUB Organoids, Emulate Inc., 3D Biomatrix Inc., Prellis Biologics Inc., 3D Biotek LLC, DefiniGEN Limited, Visikol Inc., Organovo Holdings Inc., Cellesce Ltd., AMS Biotechnology (Europe) Limited.

North America was the largest region in the organoids and spheroids market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the organoids and spheroids market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the organoids and spheroids market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Organoids and spheroids are advanced 3D cell culture systems designed to replicate the structure and function of organs and tissues. Organoids are small, simplified versions of organs created from stem cells, while spheroids are spherical clusters of cells that can model tumor environments or various tissue types. These systems are utilized for research purposes such as disease modeling and drug testing.

The primary types of these models are organoids and spheroids. Organoids are miniature organ replicas grown in vitro from stem cells, used for investigating organ development, disease mechanisms, and drug effects. Techniques for generating organoids include the extracellular matrix scaffold method, spinning bioreactor method, hanging drop method, low adherent culture plate method, magnetic levitation method, and others. Applications of these models span developmental biology, personalized and regenerative medicine, disease pathology, drug toxicity studies, and efficacy testing. Key users include the biotechnology and pharmaceutical industries, academic and research institutions, and hospitals and diagnostic centers.

The organoids and spheroids market research report is one of a series of new reports that provides organoids and spheroids market statistics, including the organoids and spheroids industry's global market size, regional shares, competitors with an organoids and spheroids market share, detailed organoids and spheroids market segments, market trends and opportunities, and any further data you may need to thrive in the organoids and spheroids industry. This organoids and spheroids market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The organoids and spheroids market includes revenues earned by entities by providing services such as drug discovery and testing, toxicology screening, personalized medicine, regenerative medicine research, cancer research, stem cell research, and gene editing studies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.